Literature DB >> 33640990

Epidemiology of molecular probes in Xpert MTB/RIF assay in Khyber Pakhtunkhwa, Pakistan.

Anwar Sheed Khan1, Muhammad Tahir Khan2, Sajid Ali5, Taj Ali Khan3, Muhammad Qasim3, Arif Malik4, Sajid Ali5, Wasim Sajjad6, Qurrat Ul Ain7, Muhammad Irfan8.   

Abstract

Regardless of a plethora of advanced diagnostics, TB and drug resistance remains a principal killer. We proposed gold nanoparticles (AuNPs) attached with probes to enhance the efficiency of GeneXpert MTB/RIF assay instead of conventional dye probes for molecular detection. A total of 15,000 samples were collected from TB suspects and subjected to Xpert MTB/RIF assay, where 6800 (45.3%) were detected as MTB positive, 280 (4.3%) were detected to harbor mutations in the RRDR, while invalid /errors were found in 690 (4.6%) cases. The mutations were detected by probe E, 199 (71.1%), while probes B and D, 30 and 26 (10% and 9%), respectively. In the Xpert MTB/RIF Assay were found mutations picked by probes E and B codons 529-533 (71%) and 512-518 (10%), respectively. The fast-rising works of TB nano-diagnostics, of Xpert probes, may improve by the applications of gold nanoparticle probes.

Entities:  

Keywords:  AuNPs; Probe; RRDR; Xpert MTB/RIF assay

Mesh:

Substances:

Year:  2021        PMID: 33640990     DOI: 10.1007/s00203-021-02242-5

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.552


  22 in total

1.  Gold-nanoparticle-probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples.

Authors:  Pedro V Baptista; Maria Koziol-Montewka; Jolanta Paluch-Oles; Gonçalo Doria; Ricardo Franco
Journal:  Clin Chem       Date:  2006-07       Impact factor: 8.327

Review 2.  Nanodiagnostics for tuberculosis detection.

Authors:  Hesham El-Samadony; Asma Althani; Mohamed Awad Tageldin; Hassan M E Azzazy
Journal:  Expert Rev Mol Diagn       Date:  2017-04-07       Impact factor: 5.225

3.  Unsuccessful Xpert® MTB/RIF results: the Nigerian experience.

Authors:  M Gidado; N Nwokoye; P Nwadike; P Ajiboye; R Eneogu; S Useni; J Onazi; A Lawanson; E Elom; A Tubi; J Kuye
Journal:  Public Health Action       Date:  2018-03-21

4.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

5.  Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid.

Authors:  F Brossier; N Veziris; V Jarlier; W Sougakoff
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

6.  Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.

Authors:  Hai Huang; Yanlin Zhang; Sheng Li; Jun Wang; Jun Chen; Zhiyun Pan; Hui Gan
Journal:  Microb Drug Resist       Date:  2017-10-20       Impact factor: 3.431

7.  Computational protein-ligand docking and virtual drug screening with the AutoDock suite.

Authors:  Stefano Forli; Ruth Huey; Michael E Pique; Michel F Sanner; David S Goodsell; Arthur J Olson
Journal:  Nat Protoc       Date:  2016-04-14       Impact factor: 13.491

8.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

9.  Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.

Authors:  Yacoob Mahomed Coovadia; Sharana Mahomed; Melendhran Pillay; Lise Werner; Koleka Mlisana
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

10.  Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.

Authors:  Elisa Ardizzoni; Emmanuel Fajardo; Peter Saranchuk; Martina Casenghi; Anne-Laure Page; Francis Varaine; Cara S Kosack; Pamela Hepple
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.